Company Description
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.
Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rheumatoid arthritis, sjögren’s disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases.
The company’s lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases.
In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform.
Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
| Country | United Kingdom |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 750 |
| CEO | Matthew Gline |
Contact Details
Address: 11-12 St. James's Square, Suite 1 London, SW1Y 4LB United Kingdom | |
| Website | roivant.com |
Stock Details
| Ticker Symbol | ROIV |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001635088 |
| CUSIP Number | G76279101 |
| ISIN Number | BMG762791017 |
| Employer ID | 98-1173944 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Eric Venker M.D., Pharm.D. | President and Chief Executive Officer of Immunovant |
| Matthew Gline | Chief Executive Officer and Director |
| Dr. Mayukh Sukhatme M.D. | President, Chief Investment Officer and Director |
| Richard Pulik | Chief Financial Officer |
| Jennifer Humes | Chief Accounting Officer |
| Dr. Frank M. Torti M.B.A., M.D. | President and Vant Chair |
| Dr. Huafeng Xu Ph.D. | Chief Technology Officer |
| Drew Kramer | Chief Information Officer |
| Josh Chen J.D. | General Counsel |
| Kelly Graff | Head of People |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 20, 2025 | 144 | Filing |
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |
| Aug 11, 2025 | 10-Q | Quarterly Report |
| Aug 11, 2025 | 8-K | Current Report |
| Aug 7, 2025 | SCHEDULE 13G | Filing |
| Aug 6, 2025 | SCHEDULE 13G/A | Filing |
| Jul 29, 2025 | ARS | Filing |
| Jul 29, 2025 | DEF 14A | Other definitive proxy statements |
| Jul 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |